Genomenon
Genomenon, Inc.
Actionable Genomic Evidence at the Gene & Variant Level Aligned with ACMG/AMP. Supporting Patient Diagnosis & Precision Medicine for Rare Disease & Cancer.
genomenon.com · Ann Arbor, MI
Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$6.0M of $10.0M
Filed2026-07-30
Days since filing66
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-07-15
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Michael KleinExecutive Officer · Director
- Mark KielExecutive Officer · Director
- Patricia GlazaDirector
- David GregorkaDirector
- Michael GrossDirector
- Brian GroarkExecutive Officer
- Sam GlobusExecutive Officer
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged60.3% sold2.6 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-243
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- Revenue Operations Analyst (Bosnia and Herzegovina)SEP 24Bosnia and Herzegovina · Finance · open 10 days
- General Interest in Genomenon for B&H: Share your resume and we'll keep it on file!SEP 24Sarajevo/Tuzla Office, B&H · Operations · open 10 days
- General Interest in Genomenon: Share your resume and we'll keep it on file!SEP 24Remote, USA · Operations · open 10 days
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-03, against 71 in the 28 days before.